Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 12/20 | 0.51 |
| ▸ | ADK | P55263 | 6/20 | 0.51 |
| ▸ | ABL1 | P00519 | 4/20 | 0.50 |
| ▸ | EGFR | P00533 | 4/20 | 0.50 |
| ▸ | ABL2 | P42684 | 4/20 | 0.50 |
| ▸ | LCK | P06239 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | TEK | Q02763 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20920813 | 1.00 | SRC (0.51) | SRCADKABL1EGFRABL2 | |
| SCHEMBL20938268 | 0.91 | ADK (0.50) | SRCADKABL1EGFRABL2 | |
| SCHEMBL20938253 | 0.91 | ADK (0.49) | SRCADKABL1EGFRABL2 | |
| SCHEMBL20938342 | 0.90 | RIPK2 (0.56) | SRCADKABL1EGFRABL2 | |
| SCHEMBL20938251 | 0.90 | RIPK2 (0.56) | SRCADKABL1EGFRABL2 | |
| SCHEMBL20917259 | 0.90 | RIPK2 (0.56) | SRCADKABL1EGFRABL2 | |
| SCHEMBL20938344 | 0.90 | ADK (0.47) | SRCADKABL1EGFRABL2 | |
| SCHEMBL22912604 | 0.90 | ADK (0.63) | SRCADKABL1EGFRABL2 | |
| SCHEMBL20916992 | 0.90 | ADK (0.63) | SRCADKABL1EGFRABL2 | |
| SCHEMBL20938255 | 0.90 | RIPK2 (0.58) | SRCADKABL1EGFRABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072628-B2 | Nucleoside analogues for the treatment of parasitic infections | UNIVERSITEIT GENT (BE) | 2021-07-27 | — | — | US | disclosed |
| US-20210024566-A1 | NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS | UNIVERSITEIT GENT (BE) | 2021-01-28 | — | — | US | disclosed |
| WO-2019076633-A1 | NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS | UNIVERSITEIT GENT (BE) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072628-B2 | Nucleoside analogues for the treatment of parasitic infections | PNP, NUDT1, SAMHD1 | SRC 4778/4885ADK 109/4885ABL1 1044/4885 |
| US-20210024566-A1 | NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS | PNP, NUDT1, SAMHD1 | SRC 4778/4885ADK 109/4885ABL1 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.